TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

ITB lecturer studies local biodiversity in anti-HIV drug research

ITB lecturer studies local biodiversity in anti-HIV drug research Building at Bandung Institute Technology (ITB) campus in Bandung, West Java. (Shutterstock/File)
News Desk (The Jakarta Post)
Jakarta   ●   Thu, July 26, 2018 2018-07-26 14:32 2093 a7124a1e87885b91d244660f9efcad70 1 News ITB,HIV,AIDS,anti-HIV-drugs,medicine,health,#health,Azzania-Fibriani Free

A lecturer at the Bandung Institute of Technology (ITB)'s Life Sciences and Technology School is currently researching Indonesia's biodiversity for potential use in anti-HIV medicines. 

Dr. Azzania Fibriani and her research team designed a compound selection system last year to identify candidates from among the archipelago's endemic biodiversity for potential use in anti-HIV drugs. Among the system's highlights is its ability and speed in simultaneously selecting a variety of compounds. Its flexibility also means that the selection system could be used at almost all molecular labs in the country, and not necessarily restricted to use in a level 3 biosafety lab.

"Using this system, researchers don't have to breed viruses, as it allows them to select the drug compounds that could serve as anti-HIV drug candidates," Azzania recently said at the ITB lab in Bandung, West Java.

Read also: ITB students devise cheat-detection system

According to the institute's online newsroom, the research is still in the development and validation phase. "In one to two years' time, this system can reach the next stage to search for alternative treatment for HIV infection," she said.

The L'Oreal Fellowship for Women in Science recognized Azzania in 2016 for her research.

For now, she is hopeful that the team can use the system to start selecting candidate compounds for testing by the end of the year, when the validation phase is expected to be completed. (kes)

NEWS PULSE